ArticleFrontiers in pharmacology2026
Integrative bioinformatics analysis identifies APOE as a candidate link between lipid dysregulation and macrophage activation in inborn errors of metabolism.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inborn errors of metabolism (IEM) are a heterogeneous group of genetic disorders characterized by metabolic dysregulation and high mortality. Despite extensive genetic discoveries, the molecular mechanisms underlying severe disease progression remain incompletely understood. Increasing evidence suggests that host metabolic states, particularly lipid dysregulation, can profoundly influence immune cell function and may contribute to impaired responses against intracellular pathogens. Methods: We integrated genomic data from four high-confidence databases (GWAS Catalog, CTD, Open Targets, and ClinVar) and identified 1,288 IEM-associated genes. Disease ontology enrichment, multi-parametric functional annotation, and cell-type enrichment analyses were performed using Open-XGR, WebGestalt, and Tabula Sapiens. Bioinformatics findings were interpreted alongside clinical and cytomorphological observations from a pair of one-year-old twins with suspected IEM and macrophage activation syndrome. No patient-specific genetic or molecular validation of APOE was available. Results: Functional annotation identified APOE as the highest-scoring gene across seven biological categories, with enrichment in lipid metabolism- and macrophage-related pathways. Cell-type enrichment demonstrated an overrepresentation of IEM-associated genes in macrophage-related reference signatures, including datasets annotated as M2 macrophages. APOE was the only gene consistently represented across macrophage, M2 macrophage, protein-lipid complex, and vasculature-associated macrophage categories. Clinical evaluation of the twin cases showed persistent hyperbilirubinemia, elevated transaminases, cholestasis, and macrophage activation. Bone marrow and cerebrospinal fluid cytology demonstrated lipid-laden monocyte/macrophage morphology. These clinical observations are concordant with lipid-handling abnormalities in macrophages but do not establish an APOE-dependent mechanism or macrophage polarization state. Conclusion: This study identifies APOE as a highly prioritized candidate gene associated with lipid metabolism pathways and macrophage-related signatures in IEM. These findings support the hypothesis that APOE-associated lipid dysregulation may contribute to macrophage dysfunction and warrant further experimental validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.